Compare Nuvalent Inc (NUVL) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.9. The key difference: Nuvalent Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| NUVL | SJNK | |
|---|---|---|
Market Cap | $9.81B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $123.96 | $25.63 |
52-Week Low | $72.16 | $24.75 |
Enterprise Value | $8.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
SJNK trades at $24.92 with no change over the past 24 hours, reflecting stability amid a bearish technical signal from moving averages. The ETF maintains a neutral stance in oscillators, with RSI levels indicating neither overbought nor oversold conditions. Recent corporate actions include scheduled dividend payments, with H2-26 set at $0.15 per share. Institutional activity shows Balefire LLC reduced its stake by 74.7% in the latest quarter, as per SEC filings dated 2026-07-21.
The outlook for SJNK is cautious due to bearish technical indicators and negative sentiment from analysts, who rate it SELL citing exhausted tailwinds from falling yields. Risks include high sensitivity to interest rate changes and credit spread volatility. Investment opportunity lies in its high-yield bond focus, but current conditions suggest limited near-term upside amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
